TY - JOUR
T1 - Recommended immunization schedules for adults
T2 - Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)
AU - Esposito, Susanna
AU - Bonanni, Paolo
AU - Maggi, Stefania
AU - Tan, Litjan
AU - Ansaldi, Filippo
AU - Lopalco, Pier Luigi
AU - Dagan, Ron
AU - Michel, Jean Pierre
AU - van Damme, Pierre
AU - Gaillat, Jacques
AU - Prymula, Roman
AU - Vesikari, Timo
AU - Mussini, Cristina
AU - Frank, Uwe
AU - Osterhaus, Albert
AU - Celentano, Lucia Pastore
AU - Rossi, Marta
AU - Guercio, Valentina
AU - Gavazzi, Gaetan
N1 - Publisher Copyright:
© 2016 Taylor & Francis.
PY - 2016/7/2
Y1 - 2016/7/2
N2 - ABSTRACT: Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of ≥ 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.
AB - ABSTRACT: Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of ≥ 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.
KW - adults
KW - elderly
KW - infectious diseases
KW - prevention
KW - vaccination
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=84965082219&partnerID=8YFLogxK
U2 - 10.1080/21645515.2016.1150396
DO - 10.1080/21645515.2016.1150396
M3 - Review article
C2 - 27135390
AN - SCOPUS:84965082219
SN - 2164-5515
VL - 12
SP - 1777
EP - 1794
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 7
ER -